Assessing interactions for fixed-dose drug combinations in subcutaneous tumor xenograft studies

Section 2 (page unavailable) says mice are euthanized when tumors reach four times their initial volume, leaving incomplete longitudinal tumor-volume data. Section 6 reports that control tumors reached this endpoint earlier than treated tumors in the examples. The paper does not say that CI cannot be calculated after a particular day when most or all control mice have been euthanized; Section 4 instead describes a confidence interval based on tumor-quadrupling times. (LLM, conf=0.85)

Section 2 (page not available) says that euthanizing mice produces incomplete longitudinal tumor-volume data and describes interpolation to estimate the time of tumor quadrupling between measurements. It does not say that interpolation patches missing tumor-volume measurements, that existing methods struggle with unbalanced data, or that the uncertainty is unmeasurable. (LLM, conf=0.84)

The Introduction says dose-response surface methods are not applicable to fixed-dose combination studies and that testing a combination’s superiority over its components does not establish drug interaction. It connects this limitation to preclinical tumor xenograft studies, but does not report that existing methods have low statistical power to detect synergy across animal studies generally. (LLM, conf=0.82)

Sections 3 (Interaction Index) and 4 (Confidence Interval) define a Bliss-based interaction index using tumor-growth delays estimated from median tumor quadrupling times. The paper does not say the index becomes undefined whenever tumors shrink; Section 3 explicitly discusses treated tumors regrowing, while Section 2 treats tumors that do not quadruple during follow-up as censored. Page numbers are unavailable in our copy. (LLM, conf=0.87)

The Introduction says some existing methods are inapplicable to fixed-dose studies or assess superiority rather than drug interaction. Section 2 describes incomplete longitudinal tumor-volume data. Neither passage says those methods impose unrealistic assumptions about tumor growth or tumor-volume data, so the stated reason for their limitations is not supported. (LLM, conf=0.73)

Section 2 (page unavailable) describes weekly tumor-volume measurements and a time-to-event endpoint; Section 3 (page unavailable) defines a local interaction index. Neither passage says that existing methods calculate a combination index from one day's tumor-volume data or that day-to-day fluctuations can switch its interpretation between synergy and antagonism. Searches for single-day calculations and fluctuating local indices found no such discussion. (LLM, conf=0.73)